IMM-27M is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase II for Breast Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback